EGFR and non-small cell lung carcinoma: The efficacy and safety of immunotherapy plus chemotherapy or antiangiogenic therapy in patients with EGFR-mutant NSCLC, especially those with high PD-L1 expression, should be further explored in clinical trials that provide strong evidence-based medicine data.